What it does
Moderna is a biotechnology company based in Cambridge, led by chief executive Stéphane Bancel. It develops medicines using messenger RNA, or mRNA: instructions that direct the body’s cells to make proteins. Depending on the product, those proteins can help prevent disease or provide a therapeutic effect.
Its commercial respiratory vaccines include Spikevax and mNEXSPIKE for COVID-19 and mRESVIA for respiratory syncytial virus, or RSV. Moderna sells vaccines to wholesalers and distributors, retailers and healthcare providers, as well as foreign governments and international organizations. In 2026, its influenza vaccine mFLUSIVA received U.S. approval, and its combined influenza and COVID-19 vaccine mCOMBRIAX received approval in Canada.
The company also develops medicines that have not yet been approved. Its pipeline covers infectious diseases, cancer and rare diseases. With Merck, Moderna is developing intismeran, an individualized cancer therapy designed around a patient’s tumor. Other candidates include a norovirus vaccine and treatments for propionic acidemia and methylmalonic acidemia, rare metabolic diseases.
Moderna’s platform combines mRNA design, delivery technology and manufacturing. Many of its medicines use lipid nanoparticles, small particles designed to protect mRNA and help deliver it into cells. The company operates manufacturing facilities and also works with outside manufacturers and development partners.
How it makes money
Moderna earns most of its revenue by selling vaccines. In 2025, COVID vaccine revenue was $1.8 billion, or 93.1% of revenue, compared with $3.1 billion in 2024. RSV vaccine revenue was $8.0 million in 2025. Sales are recorded after estimated deductions such as returns, government rebates, wholesaler chargebacks and invoice discounts.
Total revenue was $1.9 billion for 2025. For the third quarter of 2026, Moderna’s chief financial officer reported revenue of $1.3 billion, while its chief executive reported $1.4 billion.
The company also receives revenue from grants, collaborations, licensing and royalties, and manufacturing-readiness agreements. The latter pay Moderna to maintain manufacturing readiness under long-term agreements with government entities; other payments under those agreements relate to product sales. Stand-ready manufacturing revenue was $80.0 million in 2025. Its licensing and royalty revenue includes an agreement licensing COVID-related mRNA intellectual property in Japan.
Vaccine demand can recur across respiratory seasons. Moderna updates its COVID vaccine compositions based on guidance from regulators and public health bodies as the virus changes. It also sells to governments under longer-term partnerships. Some supply agreements include upfront payments that are initially recorded as deferred revenue rather than recognized immediately.
Beyond sales of approved products, Moderna works with partners to discover, develop and commercialize potential medicines. Grant and collaboration revenue has come from government-sponsored and private organizations as well as strategic alliances. Revenue from development candidates depends on the terms of those arrangements; a clinical candidate is not necessarily an approved product.
| Product or service | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| COVID | $1.8 billion | 93.1% | −41.3% |
| Stand-ready manufacturing revenue | $80.0 million | 4.12% | — |
| Grant revenue | $22.0 million | 1.13% | −40.5% |
| Collaboration Arrangement Including Arrangements With Affiliate | $13.0 million | 0.67% | −72.9% |
| Licensing and royalty revenue | $11.0 million | 0.57% | −73.8% |
| RSV | $8.0 million | 0.41% | −68.0% |
Customers and how it sells
In the United States, Moderna sells COVID and RSV vaccines primarily to wholesalers and distributors, and to a lesser extent directly to retailers and healthcare providers. Outside that commercial channel, it sells to foreign governments and international organizations. Its products ultimately reach people eligible for vaccination under the relevant approvals and recommendations.
Customer concentration is visible in the 2025 figures. FFF Enterprises accounted for 15.0% of revenue, Public Works and Government Services Canada for 13.0%, and Cardinal Health for 11.0%.
The United States accounted for $1.2 billion of 2025 revenue, or 61.7%. Rest-of-world revenue was $692.0 million, while Europe contributed $53.0 million. Moderna has long-term partnerships with the UK, Canada and Australia that include local manufacturing and vaccine supply. Its Australian and UK facilities became operational in 2025, and its Canadian facility produces drug substance for an updated Spikevax vaccine.
The company is seeking to extend distribution into additional markets. In 2026, it signed an agreement with a local manufacturer to support COVID-19 vaccine supply in Mexico. Product availability varies by country and by the scope of local regulatory approvals.
| Region | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| United States | $1.2 billion | 61.7% | −32.8% |
| Rest of world | $692.0 million | 35.6% | −18.9% |
| Europe | $53.0 million | 2.73% | −91.1% |
Suppliers and costs
Moderna makes products through its own global manufacturing network and uses third-party manufacturers. Its sites in the UK, Canada and Australia support local access to mRNA vaccines. In Canada, Moderna produces the drug substance for an updated Spikevax vaccine, while Novocol Pharma completes fill-and-finish, including pre-filled syringes. Moderna’s Marlborough, Massachusetts facility supplies clinical batches of intismeran.
Cost of sales includes raw materials, personnel, facilities, outside manufacturing, final formulation and packaging, shipping and royalties. It can also include charges for excess or obsolete inventory, inventory valuation and losses on purchase commitments. Research and development spending covers platform development, discovery, clinical studies, manufacturing technology and related digital infrastructure. Moderna also pays third parties, including clinical trial sites, consultants and contract research organizations.
The company expects to reduce costs through its production network and digital tools. In its 2026 financial framework, Moderna reduced its research and development expense expectation to $2.7 billion, citing the winding down of studies and operating efficiencies.
- Revenue$1.9B
- Cost of revenue−$868.0M
- Research and development−$3.1B
- Selling, general and administrative−$1.0B
- Operating income−$3.1B
Competitive position
Moderna largely competes with Pfizer and BioNTech in COVID vaccines; their vaccine also uses mRNA technology. It also identifies vaccines from Sanofi and Novavax as competitors. Pfizer’s COVID antiviral treatment may reduce demand for vaccines. In RSV, Moderna competes with Pfizer and GlaxoSmithKline, both of which entered the U.S. market before Moderna. Moderna says its RSV sales have been minimal to date.
Competition depends on factors including vaccine effectiveness and safety, public views of mRNA technology, storage and distribution requirements, regulatory approvals, reimbursement and production costs. Moderna also competes for alliances that can advance its pipeline.
Moderna’s platform combines proprietary mRNA sequences, lipid nanoparticle delivery technologies and manufacturing processes. The company believes shared technology and infrastructure can help it develop multiple medicines. Its commercial vaccines and manufacturing network provide experience across development and supply.
Our reading: The platform and manufacturing capabilities provide a meaningful technological base, but they do not prevent competitors from selling mRNA vaccines. Our reading: Commercial distribution and government partnerships support access to customers, while the RSV experience shows that entering after established products can limit market share. Our reading: Proprietary technology may help protect individual products and processes, but the evidence here does not establish how durable that protection will be across the portfolio.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Pfizer | COVID and RSV vaccines; COVID antiviral treatments | High |
| BioNTech | mRNA COVID vaccines | High |
| GlaxoSmithKline | RSV vaccines | High |
| Sanofi | COVID vaccines | Medium |
| Novavax | COVID vaccines | Medium |
Growth opportunities
Moderna expects growth from expanding its respiratory vaccine portfolio and geographic reach. Its influenza vaccine mFLUSIVA received U.S. approval in 2026, while mCOMBRIAX, its combined flu and COVID vaccine, is approved in Europe and Canada. A decision on filing mCOMBRIAX in the United States remains subject to further FDA discussions.
In oncology, Moderna and Merck are developing intismeran, an individualized therapy used with Merck’s pembrolizumab. In a Phase 3 melanoma study, the combination reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. Moderna is also studying the treatment in other tumor types. Its Marlborough facility was built for intismeran and has begun supplying clinical batches.
In rare disease, the company’s propionic acidemia candidate has reached target enrollment in a registrational study. Moderna has partnered with Recordati to advance that candidate through late-stage development and, if approved, global commercialization. Moderna has deferred its decision to initiate a pivotal methylmalonic acidemia trial until after the propionic acidemia readout.
The company raised its 2026 revenue growth expectation to a range of 15% to 25%. It identified mNEXSPIKE adoption and its UK, Canadian and Australian partnerships as growth drivers. For its norovirus candidate, the Phase 3 study did not meet the criteria for early success at an interim analysis; Moderna decided not to enroll an additional cohort for the coming winter season and plans to consult regulators about next steps.
- $18.5BFY2021
- $19.3BFY2022
- $6.8BFY2023
- $3.2BFY2024
- $1.9BFY2025
Structural risks
-
COVID dependence: COVID vaccines accounted for 93.1% of Moderna’s 2025 revenue. Regulatory and market uncertainty can affect vaccine demand, while competition, reimbursement and public acceptance influence sales.
-
Clinical and regulatory outcomes: Product candidates can fail to show safety or efficacy, produce inconclusive results, require additional studies or encounter delayed approvals. Early trial results do not necessarily predict later results, and advisory committee recommendations can affect commercialization.
-
Competition and access: Vaccine sales depend on effectiveness, safety, distribution, approval timing and reimbursement. Moderna entered the U.S. RSV market after competitors and has reported minimal RSV sales. Insurers may seek discounts or restrict coverage.
-
Manufacturing and supply: Moderna or its outside manufacturers may encounter problems with production, testing, storage, shelf life, shipping or product release. Manufacturing changes or insufficient clinical supplies can delay trials.
-
Cash requirements: Moderna had a net cash outflow from operations of $1.9 billion in 2025. In 2026, it raised $3 billion through a convertible note and paid $950 million to settle litigation. Development and commercialization continue to require funding.
Bottom line
Our reading
Moderna is a commercial vaccine business built on a platform it is also using to develop cancer and rare-disease medicines. COVID sales still account for most revenue, while newer vaccines and partnerships provide additional routes to customers. The longer-term opportunity depends on turning clinical candidates into approved, commercially viable products and funding that work through uncertain trial, regulatory and competitive outcomes.